AIVITA Doses First 10 Ovarian Cancer Patients with Cell-based Immunotherapy in Phase 2 Trial

AIVITA Doses First 10 Ovarian Cancer Patients with Cell-based Immunotherapy in Phase 2 Trial
The Phase 2 clinical trial evaluating AIVITA Biomedical’s cell-based immunotherapy for treating newly-diagnosed advanced ovarian cancer has dosed its first 10 patients. The study (NCT02033616) is looking to enroll 99 women at the Hoag Memorial Hospital Presbyterian in Newport Beach, California. Additional leading cancer centers may join the trial. Women with stage 3 or 4 epithelial ovarian, fallopian tube, or

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *